2022 - Consultation response on proposed changes to the guidance on, items which should not be routinely prescribed in primary care.

We support the need to review guidance to ensure it remains up to date and that Integrated Care Boards (ICBs) are supported to fulfil their duties around appropriate use of their resources. However, co-production and shared decision making should be made integral to the guidance and proposed changes in order to support ICB decision making.

2022 - Consultation response on proposed changes to the guidance on, conditions for which over the counter items should not be routinely prescribed in primary care.
We support the need to review this guidance to ensure that Integrated Care Boards (ICBs) are supported to fulfil their duties around appropriate use of their resources. However, co-production and shared decision making should be made integral to the guidance and proposed changes in order to support ICB decision making. 

2021 - Consultation response - Aligning the upper age for NHS prescription charge exemptions with the State Pension age
We oppose proposals to extend prescription charges to patients in England aged 60-65.

2021 - Consultation response - NICE review of health technology evaluation processes
We expressed concern at NICE's proposals to modify their processes to make input by patient and patient organisations more difficult.

2020 - Consultation response - NICE consultation on health technologies appraisal methods
In our comment on NICE's proposals for reviewing its health technologies appraisal methods, we made recommendations to enhance and expand its use of patient experience and feedback.

2020 - Consultation response - NICE guideline on arranging planned care
We responded to NICE's rapid-turnaround consultation on a draft guideline for arranging planned care in the context of COVID-19. We recommended numerous measures to improve patients' experiences

2020 - Consultation response - Evidence based interventions
In our response to the proposals for a second wave of restrictions to certain treatments, we expressed concern that the methodology remains unproven and relatively lacking in patient input, albeit that many of the proposals are in line with current good practice.